Zynerba Pharmaceuticals, Inc. Price Today
Zynerba Pharmaceuticals, Inc.
ZYNE
Healthcare
$18.94M
💰
Market Cap
0
💸
Price to Earnings
$-0.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
3 |
Strong Buy |
4 |
Hold |
2 |
Sell |
0 |
Strong Sell |
0 |
ZYNE Price Forecast Target
0.4 👉 10.0 +2733%
ZYNE EPS Forecast
-0.8 👉 -0.6 +-25%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
6.1% - Insiders
12.1% - Institutions
81.8% - Public
Major Fund Holders
-
💰 Vanguard Group Inc $937,228.0
-
💰 Blackrock Inc. $360,641.0
-
💰 ETF Managers Group, LLC $310,954.0
-
💰 Renaissance Technologies, LLC $244,971.0
-
💰 Millennium Management Llc $196,230.0
Stock Ideas
Daniel Loeb Portfolio
Daniel Loeb is an American billionaire businessman and founder/CEO of Third Point LLC, a global investment firm managing over $12 billion in assets through long/short equity investments and activism. As one of the world's most successful hedge fund…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Seth Klarman Portfolio
Seth Klarman's investment prowess is exemplified by his exceptional track record. Since the inception of his fund until 2008, he achieved an impressive compound return-on-investment of 20%. This remarkable achievement showcases his astute investment…📮FAQ
Some Frequently Asked Questions.
The Zynerba Pharmaceuticals, Inc. industry is Drug Manufacturers—Specialty & Generic
The Zynerba Pharmaceuticals, Inc. sector is Healthcare
The Zynerba Pharmaceuticals, Inc. forecasted predicted Price to Earnings PE ratio is -0.6
The Zynerba Pharmaceuticals, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Zynerba Pharmaceuticals, Inc. is $18.94M
There are total of 46681585 float shares with 12.1% held by Institutions and 6.1% held by insiders
The MZynerba Pharmaceuticals, Inc. forecasted Earnings per Share EPS is $-0.6
The Zynerba Pharmaceuticals, Inc. Earnings per Share EPS is -0.8
The Zynerba Pharmaceuticals, Inc. company has $0 gross profits with 0 profit margins
The Zynerba Pharmaceuticals, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Zynerba Pharmaceuticals, Inc. Revenue is $0 with 0 revenue growth
The price target for Zynerba Pharmaceuticals, Inc. stock is $10.0 for the high target and $0.4 for the low target
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, with the following breakdown:
- Buy: 3
- Strong Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 0
The Beta of Zynerba Pharmaceuticals, Inc. is 1.8
The dividend of Zynerba Pharmaceuticals, Inc. is $0
The dividend yield of Zynerba Pharmaceuticals, Inc. is 0%
The biggest institutional and mutual fund holders of Zynerba Pharmaceuticals, Inc. stock are
- Vanguard Group Inc
- Blackrock Inc.
- ETF Managers Group, LLC
- Renaissance Technologies, LLC
The Zynerba Pharmaceuticals, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0